Issue
The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.
rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration
Corresponding Author(s) : B-Y Qin
qinbyu424@126.com
Cellular and Molecular Biology,
Vol. 61 No. 1: Issue 1
Abstract
The binding of selectin to P-selectin glycoprotein ligand-1 (PSGL-1) mediates the tethering and rolling of leukocytes on the endothelium during leukocyte migration and inflammation. Recombinant human PSGL-1-Ig fusion protein (rPSGL-1-Ig) is a widely used selectin inhibitor that prevents neutrophil entry into inflamed or reperfused tissues. We hypothesized that rPSGL-1-Ig could be used to as a drug for the treatment of acute lung injury (ALI). We induced murine ALI by injecting mice with lipopolysaccharide (LPS) and then treated the mice with rPSGL-1-Ig. We determined the lung injury index, wet/dry ratio, and inflammatory cytokine level in differentially treated mice. The symptoms of LPS-induced lung injury were alleviated by rPSGL-1-Ig treatment. The histopathological index of LPS-induced lung injury improved after rPSGL-1-Ig treatment. rPSGL-1-Ig treatment also reduced the recruitment of inflammatory cells, including neutrophils, into the lung, as well as reducing the level of inflammatory cytokines. These data suggest that rPSGL-1-Ig protein has a therapeutic effect on LPS-induced lung injury.
Keywords
Recombinant PSGL-1-Ig fusion protein
LPS-induced acute lung injury
neutrophil migration.
Shao, H.-Z., & Qin, B.-Y. (2015). rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cellular and Molecular Biology, 61(1), 1–6. Retrieved from https://mail.cellmolbiol.org/index.php/CMB/article/view/630
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX